NCT05851430 Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry
| NCT ID | NCT05851430 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Galvanize Therapeutics, Inc. |
| Condition | Soft Tissue Lesion |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-06-23 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-06-23 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational registry is to assess the use and performance of Galvanize PEF technology in a real-world setting. The main questions it aims to answer are: * PEF utilization and performance * Monitor safety outcomes and inform future generation devices. Participants will undergo the PEF procedure and be followed per institutional standard of care.
Eligibility Criteria
Inclusion Criteria: 1. Subject will undergo or has undergone PEF energy delivery utilizing Galvanize technology 2. Subject is expected to be available for follow-up per the enrolling physician's standard care practices 3. For prospective cohort, subject has a life expectancy of at least 3 months; for retrospective cohort, subject has completed at least three months of imaging following the PEF procedure 4. Signed informed consent is obtained, if required by IRB Exclusion Criteria: None
Contact & Investigator
William Krimsky, MD
STUDY CHAIR
Chief Medical Officer
Frequently Asked Questions
Who can join the NCT05851430 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Soft Tissue Lesion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05851430 currently recruiting?
Yes, NCT05851430 is actively recruiting participants. Contact the research team at pseshaiah@galvanizetx.com for enrollment information.
Where is the NCT05851430 trial being conducted?
This trial is being conducted at Gilbert, United States, Rancho Mirage, United States, Naples, United States, New York, United States and 6 additional locations.
Who is sponsoring the NCT05851430 clinical trial?
NCT05851430 is sponsored by Galvanize Therapeutics, Inc.. The principal investigator is William Krimsky, MD at Chief Medical Officer. The trial plans to enroll 1,000 participants.